Paractin and Multiple Sclerosis
Monotherapy with an Andrographis paniculata composition (Paractin® capsules)
for the symptomatic relief in different chronic rheumatoid conditions and Multiple
Sclerosis: Long term follow up of 17 cases.
(l)C.F. Zarate, MD;D[1)L.C. Carcamo, MD and (2)J.C.
Bertoglio, MD.
Publication: 2012
Paractin were administered orally twice a day for an average of more than three years to this
group of 17 independently treated patients, all with a long history of active disease: 3
with Adult Rheumatoid Arthritis, 1 with Juvenile Rheumatoid Arthritis, 2 with Psoriatic Arthritis, 1
with Sjogren's syndrome, 1 with Ankylosing spondilitis and 9 with Multiple Sclerosis. Dosage: 150mg
Paractin, twice daily.
Principal Findings:
□ The intensity of joint pain and stiffness rapidly decreased at three to four weeks
in all patients with active rheumatoid diseases and was thereafter maintained significantly low
without recurrence with this therapy.
□ These clinical findings correlated with a corresponding reduction in RF, HSR and CRP.
□ The fatigue, number of relapses and progression rate of disease in the Multiple
sclerosis group also decreased significantly, which correlated with overall signs of clinical
activity and also with MR imaging.
Result:
□ After 42 weeks of treatment, long term treatment of Paractin improved symptom, serum
immunological parameters of inflammation or MR images of lesions in this group.
□ No side effects
□ Normal liver, kidney and metabolic functions.
□ Very significant improvement of fatigue and functional capacity
□ Potent control of clinical, serological and MR inflammatory parameters
□ Significant less consumption of NSAIDs
□ Presently (three and a half years later), 8 rheumatologic patients still in continuous
regular treatment only Paractin (monotherapy), all in full tolerability and remission
of clinical and numerological inflammatory parameters.
Magnetic Resonance Imaging (MRI)
Comparative imaging study of lesions
by MRI before treatment and 4 month and 26 months
□ No change in total number and no increase in size of demyelinating lesions in the brain white
matter
□ Highly significant reduction to no inflammatory activity of demyelinating lesions
Paractin is a potent inhibitor of NF-kB, a transcription factor linked to COX-2, iNOS,
and TNF-a.
NF-kB is involved in the pathogenesis of RA and other rheumatoid conditions.
Address: 707 24th Ave W
Bradenton, FL 34205
Toll Free Tel: (877) 437-2234
Toll Free Fax: (866) 278-2874
Email: info@hpingredients.com
Web Site: www.hpingredients.com
COX-2 and PGE2 production are one of the main mechanisms for the control of inflammation and pain
in RA and rheumatoid conditions by NSAIDs. Paractin is able to reduce the PGE2 production, reduce
Rheumatoid factor (RF), creatine kinase, hemoglobin, IgA, and IgM.
Andrographolide reduce TNF-a; It is known that a reduction of TNF-a canreduce significantly the RF
levels. The ability of Andrographolide to reduce antibody titer also has been demonstrated in
experimental autoimmune encephalomyelitis as an inhibition of antibodies directed to myelin antigens.
A reduction of immunoglobin, such as IgM and IgA, could also be beneficial in long-term treatment
because there is a positive correlation between the grade of cartilage damage in active RA and decrease
of RF.